



Nanotherapeutics, Inc.

Nanotherapeutics is an emerging specialty pharmaceutical company with expertise in the early-stage development of pharmaceuticals. The company employs several platform technologies to enhance drugs, imparting unique properties that cannot be matched by any other currently available process. These technologies can be employed with new chemical entities or with generic drugs and can be used with the spectrum of existing drug types ranging from small synthetic molecules to large recombinant macromolecules.

Technology

Nanotherapeutics has made significant advances in the area of nanometer-scale particle delivery, creating three proprietary drug delivery technologies: NanoQUAD™, NanoDRY™, and NanoCOAT™. These specialized proprietary techniques can improve the release rate and enhance both the rate and extent of drug uptake, thus increasing bioavailability. The consequences of these changes include more consistent drug therapy with potentially reduced dose and dose frequency requirements and fewer side effects.

Nanotherapeutics' specialized powder processing techniques offer the following pharmaceutical advantages over most drug delivery techniques:

- ◆ Broad applicability – The delivery options are applicable to a diverse group of drug molecules including proteins, peptides and other poorly absorbed compounds.
- ◆ Versatility of formulation – Various types of injectable, inhaled and oral formulations can be created using Nanotherapeutics' particle-based delivery technology.
- ◆ Improved stability – Greater than twelve months room temperature stability has been demonstrated with Nanotherapeutics' formulation technology, including those containing proteins, without loss of activity or dispersability.
- ◆ Ease of Manufacture – Scale-up to commercial quantities of production is readily obtainable at cost-effective levels.

Market Potential

Drug delivery systems generated \$49 billion in revenues in 2004, and revenues are projected to grow 10% annually. Oral controlled release provided \$25.7 billion of this total and pulmonary delivery accounted for \$9.2 billion (“The Medical & Healthcare Marketplace Guide”, Durland Healthcare Information 2004). Nanotherapeutics will compete in the drug delivery market and is well positioned for growth through partnerships with large pharmaceutical and biotech partners to bring new products to commercialization.

Nanotherapeutics, Inc.

Strategy

The core competency of Nanotherapeutics is development of novel delivery systems and the GMP manufacture of resulting formulations. The company has considerable expertise in the application of their proprietary delivery technologies to a range of compounds and materials for potential therapeutic benefit. Nanotherapeutics' strategy going forward is designed to exploit these capabilities both in collaboration with established companies and in the creation of an internal pipeline pharmaceuticals. Work with established companies will be to develop improved delivery modes for new and existing drugs and compounds. The company also plans to develop internal drug candidates through phase I/II trials, licensing these opportunities to pharmaceutical partners. Nanotherapeutics intends to retain manufacturing rights for dosage forms developed for partner companies, since many aspects of the technologies are not readily reproduced.

Management Team

Chairman and CEO – Mento A. Sponis

Mr. Sponis joined Nanotherapeutics as Chairman and CEO in 2006, previously serving as the CEO of Oragenics, Inc. from 2001 to 2005. He led Oragenics to its recent IPO on the Canadian TSX exchange and subsequent transfer to the American Stock Exchange (AMEX: ONI). Prior to this, he served as the CEO of iviGene, Inc., the President of US Biomaterials, as well as CEO of four other biotechnology companies. Mr. Sponis earned his undergraduate degree from Princeton University, and a J.D. from George Washington Law.

President and CSO – James D. Talton, Ph.D.

Dr. Talton is a co-founder of Nanotherapeutics. He is the inventor or co-inventor of Nanotherapeutics' technologies and has several authored peer-reviewed publications and book chapters involved in drug delivery systems, with a primary focus in drug analysis and controlled release formulations, pharmacokinetics, and pulmonary drug delivery. Dr. Talton received his B.S. and M.S. in materials Science and Engineering and his Ph.D. in Pharmaceutical Sciences from the University of Florida.

Contact Information

Nanotherapeutics, Inc.
12085 Research Drive
Alachua, Florida 32615
www.nanotherapeutics.com

Contact: Mento Sponis, CEO
386-462-1568
csponis@nanotherapeutics.com

For more information about this UF start-up company or other spin-off opportunities from the University of Florida, contact our UF TechConnect Coordinator:

Chris Brown, EDA University Center Coordinator
cbrown11@rgp.ufl.edu
(352) 846-1840

September 2006

